Group 1 - The Cooper Companies (COO) closed at $73.48, with a 0.8% gain over the past four weeks, and analysts set a mean price target of $92.93, indicating a 26.5% upside potential [1] - The mean estimate consists of 15 short-term price targets with a standard deviation of $7.52, where the lowest estimate is $76.00 (3.4% increase) and the highest is $105.00 (42.9% increase) [2] - Analysts show strong agreement on COO's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for COO has increased by 0.1% over the past month, with one estimate going higher and no negative revisions [12] - COO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of potential gains, it does provide a directional guide for price movement [14]

Group 1 - Omnicell (OMCL) closed at $33.09, with a 14.1% gain over the past four weeks, and a mean price target of $44.4 indicating a 34.2% upside potential [1] - The average price targets range from a low of $34.00 to a high of $55.00, with a standard deviation of $9.13, suggesting variability in analyst estimates [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 33.6% over the past month, with three estimates going higher and no negative revisions [12] - OMCL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate the direction of price movement [14]

Group 1 - Archrock Inc. (AROC) shares have increased by 3.1% over the past four weeks, closing at $24.02, with a mean price target of $31.13 indicating a potential upside of 29.6% [1] - The average of eight short-term price targets ranges from a low of $30.00 to a high of $33.00, with a standard deviation of $0.99, suggesting a consensus among analysts [2] - Analysts are optimistic about AROC's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has historically correlated with stock price movements [4][11] Group 2 - Over the last 30 days, two earnings estimates for AROC have been revised upward, leading to a 4.9% increase in the Zacks Consensus Estimate for the current year [12] - AROC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] - While the consensus price target may not be a reliable indicator of the magnitude of AROC's gains, it does provide a directional guide for potential price movement [14]

Core Viewpoint - Remitly Global, Inc. (RELY) shows significant upside potential with a mean price target of $27.11, indicating a 42.3% increase from the current trading price of $19.05 [1] Price Targets and Analyst Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $3.48, suggesting a consensus among analysts [2] - The lowest estimate is $21.00, indicating a 10.2% increase, while the highest estimate is $32.00, representing a 68% surge [2] - Analysts' price targets can be misleading, as empirical research shows they rarely indicate actual stock price movements [7][10] Earnings Estimates and Analyst Agreement - Analysts are optimistic about RELY's earnings prospects, with a strong agreement in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 33.3%, with two estimates moving higher and no negative revisions [12] Zacks Rank and Investment Potential - RELY holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not reliably indicate the extent of potential gains, they do suggest a positive direction for price movement [14]

Core Viewpoint - Shares of Shoals Technologies Group (SHLS) have seen a 2.7% increase over the past four weeks, closing at $5.76, with a potential upside indicated by Wall Street analysts' mean price target of $7.25, suggesting a 25.9% increase from the current price [1] Price Targets and Analyst Estimates - The mean estimate consists of 18 short-term price targets with a standard deviation of $1.63, indicating variability among analysts; the lowest estimate is $4.00 (30.6% decline), while the highest is $11.00 (91% increase) [2] - Analysts' price targets can often mislead investors, as empirical research shows that they rarely indicate the actual price direction of a stock [7][10] - A low standard deviation in price targets suggests a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Market Sentiment - Analysts are optimistic about SHLS's earnings prospects, as indicated by a strong consensus in revising EPS estimates higher, which correlates with near-term stock price movements [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 10.7%, with five estimates moving higher and no negative revisions [12] - SHLS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating potential upside in the near term [13]

Core Viewpoint - Ezcorp (EZPW) shares have increased by 9.8% in the past four weeks, closing at $15.64, with a mean price target of $21 indicating a potential upside of 34.3% [1] Price Targets and Analyst Consensus - The average price target consists of four estimates ranging from a low of $17.00 to a high of $25.00, with a standard deviation of $3.37, suggesting a potential increase of 8.7% to 59.9% from the current price [2] - A low standard deviation indicates a strong agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts show strong agreement in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, one estimate has increased, leading to a 2.9% rise in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - EZPW holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - The consensus price target may not be a reliable indicator of the stock's potential gain, but it does suggest a positive price movement direction [14]

Core Viewpoint - JBS N.V. shares have increased by 14.4% recently, with analysts suggesting a potential upside of 41.8% based on a mean price target of $21.4 [1][11]. Price Targets and Analyst Estimates - The mean estimate consists of 10 short-term price targets, with a standard deviation of $1.85, indicating variability among analysts [2]. - The lowest estimate is $19.50, suggesting a 29.2% increase, while the highest estimate is $26.00, indicating a potential surge of 72.3% [2]. - A low standard deviation signifies a high degree of agreement among analysts regarding the stock's price movement [9]. Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about JBS's earnings prospects, with a positive trend in earnings estimate revisions [11]. - The Zacks Consensus Estimate for the current year has risen by 1.3% over the past month, with two estimates increasing and no negative revisions [12]. - JBS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]. Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research indicates they rarely predict actual stock price movements [7][10]. - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8].

Group 1 - Dutch Bros (BROS) shares have increased by 4.5% over the past four weeks, closing at $65.4, with a mean price target of $82.88 indicating a potential upside of 26.7% [1] - The mean estimate consists of 16 short-term price targets with a standard deviation of $6.27, where the lowest estimate is $73.00 (11.6% increase) and the highest is $95.00 (45.3% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, with the Zacks Consensus Estimate for the current year increasing by 13.6% over the past month [11][12] Group 2 - The Zacks Rank for BROS is 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While price targets can be misleading, the direction implied by the consensus price target suggests potential upside for BROS [10][14] - Analysts' price targets may be influenced by business incentives, leading to overly optimistic estimates [8][9]

Core Viewpoint - Enovis (ENOV) has shown a significant price increase of 12.4% over the past four weeks, with a mean price target of $52.4 indicating a potential upside of 77.3% from its current price of $29.55 [1] Price Targets and Analyst Estimates - The mean estimate consists of 10 short-term price targets with a standard deviation of $11.51, suggesting variability in analyst predictions. The lowest estimate is $33.00 (11.7% increase), while the highest is $75.00 (153.8% increase) [2] - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about ENOV's earnings prospects, as evidenced by a positive trend in earnings estimate revisions. This correlation between earnings revisions and stock price movements supports the expectation of potential upside [11] - Over the last 30 days, three earnings estimates for the current year have been revised higher, leading to a 2.9% increase in the Zacks Consensus Estimate [12] Zacks Rank and Investment Potential - ENOV holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential for upside in the near term [13] - While the consensus price target may not be entirely reliable, the implied direction of price movement appears to be a useful guide for investors [14]

Group 1 - Rapt Therapeutics (RAPT) shares have increased by 0.5% over the past four weeks, closing at $11.74, with a mean price target of $23.6 indicating a potential upside of 101% [1] - The mean estimate consists of five short-term price targets with a standard deviation of $12.24, where the lowest estimate is $9.00 (23.3% decline) and the highest is $38.00 (223.7% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, with the Zacks Consensus Estimate for the current year increasing by 13.2% over the past month [11][12] Group 2 - RAPT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - The consensus price target may not be a reliable indicator of the stock's potential gain, but it does suggest a positive direction for price movement [14]